Nano cap Pulmatrix (PULM +4.4%) is up on below-average volume following its announcement that three sites in the U.S. have been activated for its Phase 2 study of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis in asthma patients.
17 of the 25 treatment sites are in the U.S., UK and Australia. The remaining eight are in India and Poland.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.